AbbVie delivered strong Q1 results, surpassing expectations with 12.4% revenue growth, and raised its full-year EPS guidance. The company highlighted continued momentum in Skyrizi and Renvoq, while advancing its pipeline with a focus on novel combination therapies in immunology/oncology and larger capital investments in US manufacturing. Q1 FY26 revenues grew 12.4% to $15B, beating guidance by $300M; adjusted EPS of $2.65 beat by $0.07.
AbbVie delivered strong Q1 results, surpassing expectations with 12.4% revenue growth, and raised its full-year EPS guidance. The company highlighted continued momentum in Skyrizi and Renvoq, while advancing its pipeline with a focus on novel combination therapies in immunology/oncology and larger capital investments in US manufacturing. Q1 FY26 revenues grew 12.4% to $15B, beating guidance by $300M; adjusted EPS of $2.65 beat by $0.07.
AbbVie delivered strong Q1 results, surpassing expectations with 12.4% revenue growth, and raised its full-year EPS guidance. The company highlighted continued momentum in Skyrizi and Renvoq, while advancing its pipeline with a focus on novel combination therapies in…
Q1 FY26 revenues grew 12.4% to $15B, beating guidance by $300M; adjusted EPS of $2.65 beat by $0.07.
Full-year FY26 EPS guidance raised to $14.08-$14.28 on improved operational outlook.
Skyrizi (immunology) saw sales surge 29.2% operationally, driven by leadership in psoriatic disease and IBD.
Management is raising full-year EPS guidance based on strong momentum across key franchises, signaling a positive outlook for the remainder of the year.
Management highlighted new U.S. manufacturing investments, including a $1.4 billion campus in North Carolina and $380 million in North Chicago plants, as part of AbbVie's $100 billion U.S. R&D and capital commitment. This points to a step-up in infrastructure spending to support future growth across immunology, neuroscience, oncology, and obesity.
Management repeatedly emphasized strong execution, raised full-year EPS guidance, and framed pipeline progress and commercial momentum with high confidence.
“We also now have long-term efficacy in radiographic data in psoriatic arthritis, demonstrating Skyrizzy's durable efficacy. with nearly 90% of patients showing no radiographic progression through five years of treatment.”
“Endoscopic remission was achieved by approximately 42% of patients receiving the combination at week 24.”
“The sub-Q induction achieved numerically higher results across key endpoints.”
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| EPS | FY2026 | $14.08–$14.28 | $14.18 | RAISED |
| EPS | FY2026 Q2 | $3.74–$3.78 | $3.76 | GUIDED |
| Revenue | FY2026 | $67.3B | $67.3B | RAISED |
| Issued | Metric | Target | Guide | Actual | Outcome |
|---|---|---|---|---|---|
| FY2025 Q4 | EPS | FY2026 Q1 | $2.97–$3.01 | $2.65 | Missed |
| FY2025 Q4 | Revenue | FY2026 Q1 | $14.7B | $15.002B | Met / beat |